Altogether, these analyses support that SLC30A8 LoF reduces type 2 diabetes risk through a mechanism of enhanced insulin secretion and improved overall beta cell function [9, 10], and that the magnitude of this effect may be proportional to the degree of SLC30A8 LoF. Here, INS is linked to type 2 diabetes mellitus.